Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-H3-CAR T-Cell Therapy for Pediatric Solid Tumors
NCT04897321Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2022
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 3CAR in solid tumor, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Safety of B7-H3-CAR T cells at 6 weeks. Started Jul 2022; status: recruiting.
02
Drugs
3CAR
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04897321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897321.